Skip to main content

Table 2 Clinical studies and results from immune strategies

From: Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

Immune-peptide Clinical Study Drug Combinations Patient Characteristics (pts) Results (pts%)
BCR-ABL1 as specific antigen
e14a2 PhaseI/II(125) IM CP in CyR (n = 19) (68%) < 1-log BA mRNA
e13a2, e14a2 PhaseII(126) IM CP in CyR (n = 10) (30%) < 1-log BA mRNA
(30%) MMR
(transient response)
CMLVAXB2 (e13a2) CMLVAXB3 (e14a2) PhaseII NCT00267085 IM CP in CyR (n = 10) (30%) ↓< 1-log BA mRNA
CMLVAX100 (e14a2) PhaseII(127) IM
IFN
CP in SRD (all n = 16)
IM (n = 10); IFN (n = 6)
IM: (50%) CyR and
(30%) BA UD
IFN: (83%) CyR
CMLVAX100-GMCSF PhaseII(128) IM
IFN
CP in MRD
(n = 43)
(51%) ↓50% BA mRNA
CMLb2a2–25 (e13a2) Case Study(129) CP in CyR BA UD
e13a2, e14a2 PhaseII NCT00428077 MRD
(n = 4)
(100%) < 1-log BA mRNA
e13a2 PhaseII NCT00466726 IM CP in MRD NDP
e13a2 PhaseII
NCT00004052
CP in HR NDP
LAAs
WT1 Case Study(131) IM MRD ↓ BA mRNA
PhaseI/II
NCT00004918
CP NDP
GVAX (132) IM CyR (n = 19) (68%) ↓ BA mRNA
ICB
 Ipilimumab
 Nivolumab
PhaseI
NCT01822509
CP ongoing
  1. LAAs Leukemia Associated Antigens, ICB Immune-checkpoint blockade, HR Hematological Remission, CyR Cytogenetic Remission, CP Chronic Phase, AP Accelerated Phase, BP Blast Phase, NDP No Data Posted, MRD Minimal Residual Disease, UD Undetectable, SRD Stable Residual Disease